A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy.
Phase of Trial: Phase IV
Latest Information Update: 29 May 2018
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms BioPATH
- Sponsors GlaxoSmithKline
- 24 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 14 Dec 2012 Planned End Date changed from 1 Dec 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 10 Aug 2012 Planned end date changed from 1 Aug 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.